MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma

Zhang, S Z; Cai, Lily; Li, B

doi:10.4149/bll_2017_121

Cited by 21 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the existing literature, GAS5, MEG3, RAB11B-AS1, and WWOX-AS1 are considered tumor suppressors in OS, and can inhibit OS development by suppressing OS-cell proliferation and epithelial-mesenchymal transition. [19][20][21][22] On the contrary, some other lncRNAs, such as DANCR, C2dat1, XIST, SATB2-AS1, ITGB2-AS1, MALAT1, HULC, CCAL, CBR3-AS1, ZEB1-AS1, and FGFR3-AS1, can promote OS progression by enhancing OS-cells proliferation, migration, and invasion and weakening OS-cells apoptosi.…”

Section: Discussionmentioning

confidence: 99%

<p>lncRNA FLVCR-AS1 promotes osteosarcoma growth by targeting miR381-3p/CCND1</p>

Yang¹,

He²,

Duan³

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose: This article reports on FLVCR-AS1 effects on osteosarcoma (OS) growth. Methods: Tumor tissue and adjacent normal tissue of 48 OS patients were collected. HOS and 143B cells were transfected. Gene expression was examined with qRT-PCR and Western blot. CCK8 assays and cell cloning was performed to measure cell proliferation. Cell cycle and apoptosis were assessed. Luciferase-reporter gene assays and RNA pull-down tests were used to detect targeting relationships between genes. Results: Prominently higher FLVCR-AS1 expression was found in OS tissue and cells, and was associated with poor prognosis (P<0.05, P<0.01, or P<0.001). Compared with the siCtrl group, 143B and HOS cells of the siFLVCR-AS1 group had significantly lower OD 450 values and clone numbers and obviously higher percentages of cells in the G 1 phase and apoptosis (P<0.01 or P<0.001). miR381-3p expression was directly inhibited by FLVCR-AS1, and CCND1 expression was directly suppressed by miR381-3p. Compared with the FLVCR-AS1 group, 143B cells of the FLVCR-AS1 + miR381-3p mimic group and FLVCR-AS1 + siCCND1 group showed remarkably lower OD 450 values and clone numbers obviously higher apoptosis and percentage of cells in the G 1 phase (P<0.05, P<0.01, or P<0.001). Conclusion: FLVCR-AS1 promoted OS growth by upregulating CCND1 expression via downregulation of miR381-3p.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>lncRNA FLVCR-AS1 promotes osteosarcoma growth by targeting miR381-3p/CCND1</p>

Yang¹,

He²,

Duan³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…36 While, several studies also indicated that upregulation of MEG3 as an indicator of better prognosis of osteosarcoma 37,38 as well as other types of cancers, such as prostate cancer. Further, upregulation of MEG3 was found to be significantly associated with shorter osteosarcoma OS, which indicate that it might be a crucial biomarker in osteosarcoma development.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA MEG3 play an important role in osteosarcoma development through sponging microRNAs

Jiang

Zhou

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

More and more evidence indicate long noncoding RNAs (lncRNAs) as competing endogenous RNAs (ceRNAs) to indirectly regulate messenger RNAs (mRNAs) by acting as microRNA (miRNA) sponges, which represents a novel layer of gene regulation that plays a critical role in the development of cancers. However, functional roles and regulatory mechanisms of lncRNA‐mediated ceRNAs network in osteosarcoma are still largely unknown. Here, we comprehensively compared the expression profiles of mRNAs, lncRNAs, and miRNAs between osteosarcoma and normal samples from the Gene Expression Omnibus (GEO) to elaborate related latent mechanisms. Two lncRNAs, ie, LINC01560 and MEG3, were identified to be aberrantly expressed. Importantly, MEG3 was considered as a promising diagnostic biomarker and therapeutic target for patients with osteosarcoma according to the Kaplan‐Meier analysis of another independent osteosarcoma data set from the Cancer Genome Atlas (P = 0.05). Eventually, we successfully established a dysregulated lncRNA‐related ceRNA network, including one osteosarcoma‐specific lncRNA, three miRNAs and four mRNAs. In conclusion, this study should be beneficial for improving our understanding of the lncRNA‐mediated ceRNA regulatory mechanisms in the pathogenesis of osteosarcoma and providing it with novel candidate diagnostic and therapeutic biomarkers.

show abstract

“…MEG3 is considered a vital regulator of a range of biological processes and a tumor suppressor in several types of cancer, particularly in OS (4,38). Various studies have suggested that MEG3 expression is significantly reduced in OS cells and tissues (39)(40)(41). MEG3 upregulation significantly reduces proliferation and invasion, as well as increasing apoptosis of OS cells (39,40).…”

Section: Roles Of Lncrna Meg3 In Bone Diseasesmentioning

confidence: 99%

“…Various studies have suggested that MEG3 expression is significantly reduced in OS cells and tissues (39)(40)(41). MEG3 upregulation significantly reduces proliferation and invasion, as well as increasing apoptosis of OS cells (39,40). Furthermore, the Notch and transforming growth factor (TGF)-β signaling pathways participate in MEG3-induced inhibition of OS cell proliferation and metastasis (40).…”

Section: Roles Of Lncrna Meg3 In Bone Diseasesmentioning

confidence: 99%

Long non‑coding RNA MEG3 is involved in osteogenic differentiation and bone diseases (Review)

Sun

Peng

et al. 2020

Biomed Rep

View full text Add to dashboard Cite

Osteogenic differentiation originating from mesenchymal stem cells (MSCs) requires tight coordination of transcriptional factors, signaling pathways and biomechanical cues. Dysregulation of such reciprocal networks may influence the proliferation and apoptosis of MSCs and osteoblasts, thereby impairing bone metabolism and homeostasis. An increasing number of studies have shown that long non-coding (lnc)RNAs are involved in osteogenic differentiation and thus serve an important role in the initiation, development, and progression of bone diseases such as tumors, osteoarthritis and osteoporosis. It has been reported that the lncRNA, maternally expressed gene 3 (MEG3), regulates osteogenic differentiation of multiple MSCs and also acts as a critical mediator in the development of bone formation and associated diseases. In the present review, the proposed mechanisms underlying the roles of MEG3 in osteogenic differentiation and its potential effects on bone diseases are discussed. These discussions may help elucidate the roles of MEG3 in osteogenic differentiation and highlight potential biomarkers and therapeutic targets for the treatment of bone diseases. Contents 1. Introduction 2. Roles of lncRNA MEG3 in osteogenic differentiation 3. Roles of lncRNA MEG3 in bone diseases 4. Conclusion

show abstract

MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma

Cited by 21 publications

References 25 publications

<p>lncRNA FLVCR-AS1 promotes osteosarcoma growth by targeting miR381-3p/CCND1</p>

<p>lncRNA FLVCR-AS1 promotes osteosarcoma growth by targeting miR381-3p/CCND1</p>

Long noncoding RNA MEG3 play an important role in osteosarcoma development through sponging microRNAs

Long non‑coding RNA MEG3 is involved in osteogenic differentiation and bone diseases (Review)

Contact Info

Product

Resources

About